

CURRICULUM VITAE

Lisa J. Wood PhD RN FAAN

Work Address: MGH Institute of Health Professions, School of Nursing,
Center for Health and Rehabilitation Research,
79/96 Thirteenth Street
Charlestown Navy Yard, MA 02129
Tel: 617-724-3454
Fax: 617-724-6321
e-mail: ljwood@mghihp.edu

Professional Licensure:

Oregon License # 201142628RN
Massachusetts License # RN2285617

Professional Memberships

Oregon Nurses Association
Oncology Nursing Society
American Academy of Nursing
Associate member, the Dana-Farber/Harvard Cancer Center (DF/HCC)

Citizenship: USA

Education

1989	BS Medical Microbiology	University of Dundee, Dundee, Scotland, UK
1994	PhD Molecular Biology	MRC Institute of Virology, University of Glasgow, Scotland, UK
2000	BS Nursing	Johns Hopkins University School of Nursing, Baltimore, MD

Academic Positions & Employment

1994-1996	Post-doctoral Research Fellow, Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
1999-2000	Clinical Nurse Associate, The Johns Hopkins University School of Nursing, Wald Community Nursing Center, Baltimore, MD
1996-2001	Post-doctoral Research Fellow, Department of Pediatric Hematology, The Johns Hopkins University School of Medicine, Baltimore, MD
2001-2003	Senior Research Associate, Hematology/Oncology Leukemia Program, Oregon Cancer Institute, Oregon Health & Science University, Portland, OR
2003-2010	Assistant Professor, Oregon Health & Science University, School of Nursing, Portland, OR
2003- 2010	Assistant Professor, Oregon Health & Science University Knight Cancer Institute, Portland, OR

- 2007-2012 Assistant Professor, Oregon Health & Science University, School of Medicine, Department of Radiation Medicine, Portland, OR.
- 2010-present Associate Professor, Oregon Health & Science University, School of Nursing, Portland, OR.
- 2010- 2012 Chair, Symptom Management: Integrated Learning Community, Oregon Health & Science University School of Nursing, Portland, OR.
- 2012- present Amelia Peabody Professor in Nursing Research, School of Nursing at MGH Institute of Health Professions, Boston, MA.

Honors and Awards

- 1989 First Class Honors in Medical Microbiology
- 1996 Institutional Nursing Research Service Award from the National Cancer Institute (T32) Johns Hopkins University School of Medicine.
- 1999 Barry J. Wood Young Investigator of the year Award for Post-Doctoral Research, Johns Hopkins University School of Medicine.
- 1999 Undergraduate Merit Scholarship, Johns Hopkins University School of Nursing
- 1999 Provost Undergraduate Research Award, Johns Hopkins University
- 2000 Nursing Research Award, Johns Hopkins University School of Nursing
- 2000 Alumni Association Community Service Award, Johns Hopkins University School of Nursing
- 2000 Sigma Theta Tau, International Honor Society of Nursing
- 2012 Fellow of the American Academy of Nursing (FAAN)

Publications

1. Wood LJ, Baxter MK, Plafker SM, Gibson W. Human cytomegalovirus capsid assembly protein precursor interacts with itself and with the major capsid protein through two different domains. J. Virology 1997;71:179-190.
2. Wood, LJ, Maher JF, Bunton TE, Resar LM. The Oncogenic properties of the HMGI gene family. Cancer Research 2000, 60:4256-61.
3. Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, Bunton TE, Williams JB, Resar LM. *HMG-I/Y*, a new c-Myc target gene and potential oncogene. Mol. Cell Biol. 2000; 20:5490-502.
4. Dinulescu D, Wood LJ, Loriaux M, Shen L, Corless CL, Jauron-Mills L, Gross AL, Ren R, Deininger MW, Druker BJ. C-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene 2003; 22:8852-60.
5. Xu Y, Bhattacharya R, Tesfaye A, Felder T, Wood LJ, Huso D, Resar, LMS. Transgenic mice overexpressing *HMG-I* in lymphoid tissue develop lymphoid hyperplasia and malignancy. Cancer Research; 2004, 64: 3371-3375.
6. Wood LJ, Nail LM, Perrin NA, Elsea CR, Fischer A, & Druker BJ. The cancer chemotherapy drug etoposide (VP-16) induces pro-inflammatory cytokine production and sickness behavior-

like symptoms in a mouse model of cancer chemotherapy related symptoms. Biological Research for Nursing, 2006; 8:157-169.

7. Wood LJ, Nail LM, Glistler A, Winters KA & Elsea CR. Cancer Chemotherapy Related Symptoms: Evidence to Suggest a Role for Pro-Inflammatory Cytokines. Oncology Nursing Forum, 2006; 33:535-542.
8. Griswold IJ, Bumm T, O'Hare T, Corbin AS, Stoffregen E, Moseson E, Wood LJ, Druker BJ and Deininger MW. Kinase domain mutants of BCR-ABL: altered transformation potency irrespective of sensitivity to imatinib. Molecular & Cellular Biology, 2006, 26:6082-93.
9. Bumm TGP, Elsea CR, Corbin AS, Loriaux M, Sherbenou D, Wood LJ, Deininger J, Silver RT, Druker BJ & Deininger MWN. Characterization of Murine JAK2^{V617F}-Positive Myeloproliferative Disease. Cancer Research, 2006; 66: 11156-11165.
10. Ross AM, Hurn P, Perrin N, Wood LJ, Carlini W, Potempa K. Evidence of the Peripheral Inflammatory Response in Transient Ischemic Attack Patients. Journal of Stroke and Cerebrovascular Disease 2007, 16(5):203-7
11. Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R, and Resar LMS. HMGA2 participates in neoplastic transformation in human lung cancer. Molecular Cancer Research 2008, 6(5):743-50.
12. Elsea CR, Roberts D, Errington DM, Druker BJ, & Wood LJ. Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS ONE 2008, 3(6):e2355.
13. Wood LJ, Winters-Stone K, Nail LM. Does muscle-derived interleukin-6 mediate some of the beneficial effects of exercise on cancer treatment related fatigue? Oncology Nursing Forum. 2009, 36(5):519-24.
14. Hillion J., Wood L.J., Mukherjee M., Bhattacharya R., di Cello F, Kowalski J., Elbahloul O., Segal J., Poirier J., Rudin C., Dhara S., Belton B., Joseph B., Zucker S., and Resar L.M. Up-regulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large cell lung cancer. Molecular Cancer Research, 2009, (7), 1803-12.
15. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, , Burns CJ, Fantino E, Deininger MW. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative disorder. Blood, 2010 Apr 12 (Epub ahead of print).
16. Ross RL, Jones KD, Bennett RM, Ward RL, Druker BJ, & Wood LJ. Preliminary Evidence of Increased Pain and Elevated Cytokines in Fibromyalgia Patients with Defective Growth Hormone Response to Exercise. The Open Immunology Journal, 2010, (3), 9-18.

17. Ross RL, Jones KD, Ward RL, Wood LJ & Bennett RM. Atypical depression is more common than melancholic in fibromyalgia: an observational cohort study. BMC Musculoskeletal Disorders, 2010 11:120.
18. Seo JH, Wood LJ, Agarwal A, O'Hare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ. A specific need for CRKL in p210^{BCR-ABL}-induced transformation of mouse hematopoietic progenitors. Cancer Research, 2010 70:7325-35.
19. Farley S., Wood LJ & Iordanov M. An Epidermotypic Model of Interface Dermatitis Reveals Individual Functions of Fas Ligand and Gamma Interferon in Hypergranulosis, Cytoid Body Formation, and Gene Expression. Am J Dermatopathol. 2011 May;33(3):244-50.
20. Sauter AD, Wood LJ, Wong J, Iordanov M, and Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1 β through activation of the NLRP3 inflammasome. Cancer Biol Ther. 2011 Jun 15;11(12):1008-16.
21. Wong J, Smith LB, Magun EA, Engstrom T, Kelley-Howard K, Jandhyala DM, Thorpe CM, Magun BE, Wood LJ. Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin. Cancer Biol Ther. 2013 Jan;14(1):56-63
22. Wood LJ, and Weymann K. Inflammation and neural signaling: Etiologic mechanisms of the cancer treatment related symptom cluster. Curr Opin Support Palliat Care, Curr Opin Support Palliat Care. 2013 Mar;7(1):54-9.
23. Zick SM, Zwickey H, Wood L, Foerster B, Khabir T, Wright B, Ichescio E, Sen A, & Harris RE. Preliminary differences in peripheral immune markers and brain metabolites between fatigued and non-fatigued breast cancer survivors: a pilot study. Brain Imaging & Behavior 2013 Nov 13. [Epub ahead of print]
24. Weyman KB, Wood LJ, Zhu X, & Marks DL. A role for orexin in cytotoxic chemotherapy-induced fatigue. Brain, Behavior & Immunity, 2014 Mar;37:84-94.
25. Smith LB, Leo MC, Anderson C, Wright TJ, Weymann KB, & Wood LJ. The role of IL-1 β and TNF- α signaling in the genesis of cancer treatment related symptoms (CTRS); a study using cytokine receptor-deficient mice. Brain, Behavior & Immunity, 2014;38:66-76
26. Elsea CR., Kneiss JA., & **Wood LJ**. Induction of IL-6 by cytotoxic chemotherapy is associated with loss of lean body and fat mass in tumor-free female mice. Biol Res Nurs. 2014 Nov 18. pii: 1099800414558087. [Epub ahead of print] PMID: 25406461. PMCID: Pending.
27. Wong, J., Tran, L.T., Magun, E.M., Magun, B.E. & **Wood, L.J.** (2014). Production of IL-1 β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine. Cancer Biol. Ther. 15(10):1-9. PMCID: PMC4130732.

28. Sturgeon JA., Darnall BD., Zwickey H., **Wood LJ.**, Hanes D., Zava D., & Mackey SM. Pro-Inflammatory Cytokines & DHEA-S in Women with Fibromyalgia: Impact of Psychological Distress and Menopausal Status. Journal of Pain Research. J Pain Res. 2014 Dec 4;7:707-16
29. Torgrimson-Ojerio B., Ross RL., Dieckmann NF., Avery S., Bennett RM., Jones KD., Guarino AJ., & **Wood LJ.** Preliminary evidence of a blunted anti-inflammatory response to exhaustive exercise in fibromyalgia. J. Neuroimmunol. 2014 Dec 15;277(1-2):160-7.
30. Liu X, Kenkare K, Li S, Desai V, Wong J, Luo X, **Wood LJ**, Xu Y, & Wang QM. Increased Th17/Treg Ratio in Poststroke Fatigue. Mediators of Inflammation. 2015, Article ID 931398, 9 pages, 2015. doi:10.1155/2015/931398

Manuscripts in Review

1. Luo L., Lu AM, Zhang XF, Gao XF, Gu YR, Wang Y, Xu HD, Wood LJ, Qin ZH. Exercise ameliorates age-related cognitive dysfunction through autophagy-dependent mitochondria quality control. Journal of Gerontology: Biological Sciences (In Revision)
2. McDonald T., Hung A., Thomas Jr. C., Wood LJ. Localized external beam radiation (EBRT) to the pelvis induces systemic IL-1 β and TNF- α production in a murine model: TNF- α signaling as a biomarker of EBRT induced fatigue. Radiation Research
3. Emma B. Holliday, Nathan F. Dieckmann, Tasha L. McDonald, Arthur Hung, Charles R. Thomas, Jr, and Lisa J. Wood. Relationship between fatigue, sleep quality and inflammatory cytokines during external beam radiation therapy for prostate cancer: a phase II study. Int J Radiat Oncol Biol Phys or Radiotherapy & Oncology.
4. John Wong, Bruce Magun and Lisa Wood, Lung inflammation induced by toxins: a mini-review, American Journal of Respiratory Cell and Molecular Biology (Submitted), 2015.

Manuscripts in Preparation

1. Wood LJ., Naam-Nagda N., Shapira L., Tran L., Wong J., Desmond A., & Taghian A. Serum IL-6, IGF-1, changes in body composition and fatigue level in women undergoing treatment for breast cancer.
2. Hill A., Murray S., Smart S., Naam-Nagda N., Shapira L., Tran L., Wong J., Desmond A., Taghian A., & Wood LJ. Persistent cancer treatment related fatigue in women undergoing cytotoxic chemotherapy for breast cancer is not associated with evidence of cytomegalovirus reactivation.
3. Wood LJ., Naam-Nagda N., Shapira L., Tran L., Wong J., Desmond A., & Taghian A. Real time monitoring of fatigue and sleep quality in women undergoing cytotoxic chemotherapy for breast cancer.
4. Winters-Stone KD., Wood LJ. Dieckmann N., & Dobek J. The effect of strength training on body composition and serum cancer survival markers in breast cancer survivors.

Research Grants

ACTIVE

(Wood, PI)

9/28/10-6/30/15

5R01NR012479-02, The National Institute for Nursing Research

Mechanisms of Cancer Treatment Related Symptoms. The purpose of this grant is to use both clinical and pre-clinical approaches to understanding the role of inflammatory cytokines and chemokines in cancer treatment related symptoms.

(Wood/ Magun MPI)

9/1/12 – 6/30/16

1R01NR013171-01, National Institute of Nursing Research

Targeting IL-1beta as a strategy for symptom control in cancer. The purpose of this 4-year study is to determine whether mechanistically distinct cytotoxic chemotherapeutic agents trigger cancer treatment related symptoms because they share a common ability to activate the IL-1 signaling/NLRP3 inflammasome pathway.

(Winters-Stone/Wood, MPI)

2/1/12-2/1/16 (NCE)

1R21CA164661-01, National Cancer Institute

Influence of physical exercise on inflammatory biomarkers and adiposity in cancer survivors. The purpose of this grant is to determine whether physical exercise impacts serum markers of cancer recurrence in cancer survivors post-treatment.

(Pirl, PI)

R25 CA181000-01 National Cancer Institute

7/1/14- 6/30/19

Workshop on Research Methods in Supportive Oncology. The goal of this study is to develop, implement, and evaluate an annual workshop for a national multidisciplinary audience of junior faculty to teach essential research skills and protocol writing for supportive oncology studies.

Role: Investigator

IN PREPARATION

(Wood, Wall, MPI)

R21 NIH

The impact of adjuvant cytotoxic chemotherapy on balance in women undergoing treatment for breast cancer. We propose that CTRF is caused in part by chemotherapy induced damage to the vestibular system; a sensory system that maintains the position of the eyes, body, and limbs in reference to head position. To test this hypothesis we plan to examine the relationship between CTRF and changes in vestibular system dysfunction in women undergoing chemotherapy for breast cancer. Understanding whether CTRF is associated with vestibular system deficits could lead to new treatment strategies.

(Winters-Stone, PI)

RO1 NIH

Comparing exercise modalities on markers of survival in men with prostate cancer.

The primary purpose of the proposed study is to compare the efficacy of common, but distinct exercise modalities on biomarkers of prostate cancer progression.

Role: Co-Investigator

(Ye, PI)

RO1 NIH

Self-management for aromatase inhibitor-induced arthralgia in breast cancer survivors.

Role: Co-Investigator

COMPLETED

(Wood/ Hill, MPI)

7/1/11-6/30/13

Department of Defense Breast Cancer Research Program, Collaborative Idea Award

Cytokine response to subclinical cytomegalovirus reactivation as a cause of severe fatigue in women undergoing chemotherapy for breast cancer. The purpose of this grant is to examine the relationship between cytomegalovirus (CMV) reactivation and fatigue in women undergoing cytotoxic chemotherapy for breast cancer.

(Wood, Jones MPI)

9/1/2009-8/31/2011

1R21AR056751-01, The National Institute of Arthritis & Musculoskeletal and Skin Diseases.

The neuroendocrine & inflammatory cytokine response to exercise in fibromyalgia. The purpose of this grant is to determine whether systemic inflammation underlies the increased fatigue and pain in people with fibromyalgia following strenuous exercise.

(Wood, PI)

7/1/2007-6/30/2010

R21: The National Institute of Nursing Research 1R21NR010363-02

The Role of Inflammatory Cytokines in Fatigue Associated with External Beam Radiation Therapy for Prostate Cancer. Using a translational research approach to determine the relationship between treatment-related inflammatory cytokine production and treatment related fatigue.

(Wood, PI)

7/1/2005-6/30/2010

American Cancer Society RSGPB-05-212-01-CPPB

The Role of Cytokine Deregulation in Cancer Treatment Related Fatigue. Our long-range goal of this program of research is to develop targeted therapies to effectively treat and manage cancer related symptoms, including fatigue. To this end, we have developed an innovative murine model to experimentally evaluate the associations among cancer and its treatment.

(Wood, PI)

3/1/2007-2/28/2010

Oregon Clinical & Translational Research Institute

The Role of IL-6 in Breast Cancer Treatment Associated Loss of Lean Body Mass. Our preclinical data implicates IL-6 in the loss of lean body mass in women undergoing systemic antineoplastic chemotherapy for breast cancer. The purpose of this one-year study is to examine this relationship in a clinical setting.

(Wood, PI)

2/1/2007-12/31/2009

Collins Medical Trust Foundation

The Role of Interleukin-6 in Fatigue associated with Muscle damaging Exercise. The purpose of this study is to generate clinical data to support a role for interleukin-6 in the loss of muscle wasting in women undergoing adjuvant breast cancer chemotherapy. Our findings from this clinical study will shape our pre-clinical studies funded by the ACS grant. The data generated from both the clinical and pre-clinical studies which will run in parallel will form the basis of future grant applications.

(Wood, PI)

9/13/05 – 9/12/06

OHSU - Vertex Pharmaceuticals

Moderation of Cancer Related Symptoms Using p38 MAPK or Dual p38 MPK/JNK Inhibitors. We propose a novel and innovative use for inhibitors of the p38 and JNK signaling pathways in moderating the symptoms associated with cancer and its treatment. The long-range goal of this line of research is to effectively treat and manage cancer related symptoms.

(Nail, PI)

9/1/03 - 8/31/04

National Institute of Nursing Research 1P20 NR07807-03

Chemotherapy Associated Fatigue and Cytokine Deregulation in Mice. To determine the role of cancer chemotherapy in fatigue and cytokine deregulation in mice.

Role: Subproject Principal Investigator

INVITED SPEAKER/ VISITING PROFESSOR

1. Johns Hopkins University School of Nursing, May 5th-10th, 2014.
2. University of Pennsylvania, School of Nursing, Office of Nursing Research Colloquium. March 6th, 2014.

Presentations at Professional Meetings

1. KB. Weymann¹, L.J. Wood^{1,2}, X. Zhu³, DL. Marks³ Cytotoxic chemotherapy induces hypothalamic inflammation and suppression of orexin neuron activity: a potential mechanism of cancer treatment related fatigue. The Oncology Nursing Society 38th Annual Congress, Washington DC, April 25th-28th, 2013.
2. L.J. Wood, J.Wong, T. Engstrom Jr., K. Kelley-Howard, E. Magun and B. Magun. Cytotoxic cancer chemotherapeutic agents induce IL-1 β production by immune cells. Western Institutes of Nursing Annual Communicating Nursing Research Conference, April 18–21, 2012, Portland, OR
3. F. A. Siddiqui, S. K. Chennupati, T. L. McDonald, C. R. Thomas, A.Y. Hung, L.J. Wood. TNF- α deficiency as protection against sickness behavior related to external beam radiation of the pelvis in mice. Genitourinary Cancers Symposium February 2-4, 2012, San Francisco, CA.
4. G.P. Keller, L.M. Nail, K.S. Lyons, L.J. Wood, D. Rohlman. Measurement Issues in the Study of Risk Factors for Deficits in Neuropsychological Function Related to Chemotherapy. The Nursing Honor Society, Sigma Theta Tau International, 41st Biennial Convention, 29th Oct-2nd Nov., 2011, Grapevine, Texas, USA.
29 October - 2 November 2011
5. F. A. Siddiqui, S. K. Chennupati, T. L. McDonald, C. R. Thomas, A. Hung, L. Wood. A Prospective Phase II Study Evaluating the Relationship of Fatigue and Plasma Inflammatory Cytokine Levels In Prostate Cancer (PC) Patients Undergoing External Beam Radiation Therapy (EBRT). American Society for Therapeutic Radiation Oncology, 53rd Annual Meeting, October 2-6, 2011 - Miami Beach Convention Center, Miami Beach, Fla.
6. F. A. Siddiqui, S. K. Chennupati, T. L. McDonald, C. R. Thomas, A.Y. Hung, L.J. Wood TNF- α deficiency does not protect mice from sickness behavior related to external beam radiation of the

pelvis. 97th Annual Meeting of the Radiological Society of North America, November 27-December 2, Chicago, Illinois.

7. Sauter AD, Wood LJ, Wong J, Jordanov M, and Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1 β through activation of the NLRP3 inflammasome. NINR/NCI Joint Conference *Symptom Mechanisms, Measurement and Management Conference*. May 12th, 2011, Bethesda, Washington DC.
8. L.J. Wood, invited speaker- Neuroendocrine and immune dysfunction as a cause of persistent cancer treatment related symptoms . At Long Term Effects of Cancer Treatment: Surveillance, mechanisms, and interventions. June 10, 2011, Fred Hutchinson Cancer Research Center, Arnold Bldg., Seattle, Washington.
9. L. J. Wood, invited speaker- The relationship between inflammatory cytokine response to radiation therapy and cancer treatment related fatigue. Pacific North West Prostate Cancer SPORE Advisory Board Meeting, Fred Hutchinson Cancer Research Center, Seattle, WA, November 9-10, 2009.
10. L. J. Wood, Symposium Speaker - Animal Models of Cancer and Cancer Treatment Symptoms. The 10th Annual Conference of Cancer Nursing Research, Orlando, FL, February 12-14, 2009.
11. L.J. Wood, T. McDonald, D. Roberts, X. Han, A. Hung and C.R. Thomas Jr. Pelvic Irradiation Induces a Systemic TNF- α Response and Sickness Syndrome in Mice: Implications for Cancer Treatment Related Fatigue. International Journal of Radiation Oncology Biology Physics Volume 72, Issue 1, Supplement 1, 1 September 2008, Pages S701-S702 Proceedings of the American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, American Society for Therapeutic Radiology and Oncology 50th Annual Meeting.
12. T. L. McDonald, A. Hung, D. A. Roberts, M. Loriaux, B. Druker, C. R. Thomas, L. J. Wood. Determining the relationship between inflammatory cytokine response to radiation therapy and cancer treatment related fatigue, 2008 Genitourinary Cancers Symposium February 14–16, 2007, in San Francisco, California
13. Collin R. Elsea, Daniel Roberts, Nancy A. Perrin, Lillian M. Nail, Charles R. Thomas Jr., Brian J. Druker, Lisa J. Wood. Induction of interleukin-6 by adjuvant breast cancer treatment in mice promotes loss of lean body mass via down-regulation of insulin-like growth factor I. The 2007 American Association of Cancer Research Annual Meeting, Los Angeles, CA, April 14-18, 2007
14. David M. Errington, Collin R. Elsea, Daniel Roberts, Charles R. Thomas Jr., Brian J. Druker, & Lisa J. Wood. Development of a mouse model to determine the role of IL-1 β , TNF-a, and IL-6 in fatigue associated with localized external beam radiation (EBRT) for prostate cancer. The 2007 American Association of Cancer Research Annual Meeting, Los Angeles, CA, April 14-18, 2007
15. Collin R. Elsea, Daniel Roberts, Nancy A. Perrin, Lillian M. Nail, Charles R. Thomas Jr., Brian J. Druker, Lisa J. Wood. Induction of interleukin-6 by adjuvant breast cancer treatment in mice promotes loss of lean body mass via down-regulation of insulin-like growth factor I: the role of

AMP-activated protein kinase (AMPK). The 7th AACR-JCA Joint Conference, Waikoloa, Hawaii, January 21-25, 2007.

16. Wood LJ, Nail LM, Elsea CR, Fischer A, Perrin NA, & Druker BJ. The cancer chemotherapy drug etoposide (VP-16) induces pro-inflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy related symptoms. The 2006 American Association of Cancer Research Annual Meeting, Washington, DC, April 2-6, 2006.
17. M. MacPartlin, T. O'Hare, T. Bumm, V. Goss, K. Lee, A. Corbin, E.A. Stoffregen, C. Smith, K. Johnson, E. Moseson, I. Griswold, L. Wood, R. Polakiewicz, Brian J. Druker, and Michael W.N. Deininger. Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib. Blood (American Society for Hematology Annual Meeting Abstracts), Nov 2006; 108: 4796.
18. Thomas G.P. Bumm, Collin Elsea, Lisa G. Wood, Daniel W. Sherbenou, Ian J. Griswold, Marc Loriaux, Brian J. Druker, and Michael W. Deininger. JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice. Blood (The American Society for Hematology Annual Meeting Abstracts), Nov 2005; 106: 376.
19. Thomas G.P. Bumm, Jonathan VanDyke, Marc Loriaux, Carolyn Gendron, Lisa J. Wood, Brian J. Druker, and Michael W.N. Deininger. TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder. Blood (American Society of Hematology Annual Meeting Abstracts), Nov 2007; 110: 675.
20. Shadmehr Demehri, Thomas O'Hare, Lisa J. Wood, Marc Loriaux, Brian J. Druker, and Michael W. Deininger. BCR-ABL Lacking the Pleckstrin Homology (PH) Domain of BCR Induces a More Aggressive Leukemia Than P210^{BCR-ABL} in a Murine Model of CML. Blood (American Society of Hematology Annual Meeting Abstracts), Nov 2004; 104: 2564.
21. Wood LJ, Nail LM, Elsea CR, Fischer A, Perrin NA, & Druker BJ. The cancer chemotherapy drug etoposide (VP-16) induces pro-inflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy related symptoms. Mechanisms & Treatment of Cancer-Related Symptoms. Houston, Texas; Sept. 10-12, 2005.
22. Wood LJ, Nail LM, Elsea CR, Fischer A, Perrin NA, & Druker BJ. Development of a murine model to determine the role of pro-inflammatory cytokines in cancer related symptoms. The 8th National Conference on Cancer Nursing Research. Fort Lauderdale, Florida; Feb 3-5, 2005.
23. Wood LJ & Nail LM. The effect of cancer chemotherapy on voluntary wheel-running activity in mice. Mechanisms & Treatment of Cancer-Related Symptoms. Houston, Texas; Feb 20-22, 2004.
24. Xu Y, Huso D, Wood LJ, Mukherjee M, Kaur H, Resar LMS. HMG-I/Y: A c-Myc target gene and oncogene involved in lymphoid malignancy. Third International Workshop on the HMGA Proteins in Cell Transformation and Differentiation Naples, Italy; May 24, 2002.
25. Mukherjee M, Wood LJ, Dolde CE, Cho C, and Resar LMS. The role of HMG-I/Y in the transformed phenotype of human lung and breast cancer. Foundation for Advanced Cancer Studies, Seventeenth Annual Meeting on Oncogenes, Hood College, Frederick, MD. 2001.
26. Wood LJ, Xu Y, and Resar LMS. HMG-I/Y: A c-Myc target gene and putative oncogene involved in lymphoid malignancy. 2001 *J Pediatr Hematol Oncol* 23: A3. and *Pediatr Res*.

27. Mukherjee M, Xu Y, Wood LJ, Dolde CE, Resar LMS. (2000, June 22-25th). HMG-I/Y: A c-Myc Target Gene Down-regulated in Myc-deficient Fibroblasts. Poster presentation at the Foundation for Advanced Cancer Studies, Sixteenth Annual Meeting on Oncogenes, The Salk Institute, La Jolla, San Diego, CA
28. Mukherjee M, Wood LJ, & Resar LMS.(2000, June 22-25). The role of the HMG-I/Y in Human lung cancer. Poster presentation at the Foundation for Advanced Cancer Studies Sixteenth Annual Meeting on Oncogenes, The Salk Institute, La Jolla, San Diego, CA.
29. Wood, LJ, Dolde CE, Maher JF, Bunton TE, Williams JB, Resar, LMS. (1999, 22-27th June). HMG-I/Y, a new c-Myc target gene and potential oncogene. Paper presentation at the Foundation for Advanced Cancer Studies, Fifteenth Annual Meeting on Oncogenes, Hood College, Frederick, MD.
30. Wood, LJ, Dolde CE, Maher JF, Bunton TE, Williams JB, Resar, LMS. (1999, April 17th). HMG-I/Y, a new c-Myc target gene and potential oncogene. Poster presentation at the Young Investigator of the Year Awards, Johns Hopkins University School of Medicine, Baltimore, MD.
31. Wood, LJ., Bunton TE., Maher JF, Resar LMS. (1998, June 24-27). The oncogenic properties of the HMGI family of chromosomal proteins. Paper presentation at the Foundation for Advanced Cancer Studies, Fourteenth Annual Meeting on Oncogenes, The Salk Institute, La Jolla, San Diego, CA.
32. Wood LJ, Maity A, Williams JB, Resar LMS (1997, June 18-21). HMG-I/Y: A new c-Myc target gene up-regulated in cell growth and neoplastic transformation. Poster presentation at the Foundation for Advanced Cancer Studies, Thirteenth Annual Meeting on Oncogenes, Hood College, Frederick, MD.
33. L.M.S. Resar, Maity, A., Wood LJ, and J.B. Williams. Regulation of the delayed-early gene HMG-I/Y by c-Myc and Max. The American Society for Hematology, 38th Annual Meeting, Orlando, Fl. Blood 1997, (Suppl. 1). 88:556a.

Courses Taught

2005-2006 NURS607BB: Pre-dissertation Seminar

This doctoral seminar provides a forum for scholarly exchange to facilitate the synthesis and integration of doctoral course work and experience in the conduct of research. The emphasis is on the development of a dissertation research proposal. First year students will have the opportunity to identify faculty mentors, to develop and refine specific aims, and to review the literature for drafting a background and significance section. Second- and third-year students will be able to refine their work from the first year and begin to develop the methods for their dissertation work. The seminar will provide all students with the opportunity for the review and critique of scholarly work in process. (1 Credit).

2008 NURS625: Design & Analysis for Intervention in Nursing,

This course focuses on the development and conduct of nursing intervention studies. Experimental and quasi-experimental design in nursing research and the analysis approaches that are commonly used with these designs are emphasized. Special attention will be given to the development and description of independent variables and the selection and measurement of dependent variables. (3 Credits)

2009-2012 **NURS230: Clinical Pharmacology I**

This course introduces the theoretical background that enables students to provide safe and effective care related to drugs and natural products persons throughout the lifespan. Students will learn to make selected clinical decisions in the context of nursing regarding using current, reliable sources of information, understanding of pharmacokinetics and pharmacodynamics, developmental physiologic considerations, monitoring and evaluating the effectiveness of drug therapy, teaching persons from diverse populations regarding safe and effective use of drugs and natural products, intervening to increase therapeutic benefits and reduce potential negative effects, and communicating appropriately with other health professionals regarding drug therapy. Drugs are studied by therapeutic or pharmacological class using an organized framework. (3 Credits)

2009-2012 **NURS231: Clinical Pharmacology II.**

This sequel to Clinical Pharmacology I continues to provide the theoretical background that enables students to provide safe and effective care related to drugs and natural products to persons throughout the lifespan. Students will learn to make selected clinical decisions regarding using current, reliable sources of information, monitoring and evaluating the effectiveness of drug therapy, teaching persons from diverse populations regarding safe and effective use of drugs and natural products, intervening to increase therapeutic benefits and reduce potential negative effects, and communicating appropriately with other health professionals regarding drug therapy. The course addresses additional classes of drugs and related natural products and physiological conditions (e.g. postpartum depression and schizophrenia) not contained in Clinical Pharmacology I. (3 Credits)

2009-2010 **NURS721 Genomics in Healthcare**

This course reviews and analyzes genetic influences and determinants affecting the health of individuals, families, and communities. Social, political, legal, and ethical factors will be examined. Application to healthcare practice is stressed. (2 Credits)

2010 **NURS607H Special Topics: Biological Measurement in Nursing Research**

This seminar is designed to provide an overview of current research on select biological measures relevant to nursing research. The seminar comprises 5 modules: 1) An overview of select topics in molecular genetics and cell biology, 2) Genetic variation: Single nucleotide polymorphisms in health & disease, 3) Epigenetics " Nature or Nurture", 4) Genomics and proteomics: nursing implications for disease prevention and management and 5) Animal models research issues in animal models of human disease. (3 Credits)

Professional Service Activities

Manuscript Reviewer

2006	Expert Opinion on Investigational drugs
2006	British Journal of Cancer.
2007	Journal of Experimental Therapeutics and Oncology.
2008	Experimental and Molecular Pathology
2008	Scandinavian Journal of Medicine and Science in Sports
2008	European Journal of Pharmacology
2008	PLoS ONE
2009	Journal of Inflammation Research
2009-Present	Biological Research for Nursing

2010 Integrative Cancer Therapies
 2010 Expert Opinion on Pharmacotherapy
 2011 Neuroimmunomodulation.
 2011, 2014 Psychoneuroendocrinology.
 2011, 2014 Research in Nursing & Health
 2013 BMC Complementary and Alternative Medicine

Research Grant/ Scholarship award Reviewer

2007 Ad-hoc reviewer American Society for Clinical Oncology Foundation Grant Program.
 2008 Thrasher Research Fund.
 2007-2012 Medical Research Foundation of Oregon, New Investigator and Early Clinical Investigator Grants.
 2012 Ad hoc reviewer NINR Initial Review Group (NRRC 57)
 June 2013 NINR Initial Review Group (NRRC 57)
 Nov. 2013 NINR Initial Review Group (NRRC 58)
 2014-2017 Member, National Institute of Nursing Research Initial Review Group (NRRC)
 2014 Rebecca Colvin Prize scholarly project review committee member.
 2014-Present Member, National Institute of Nursing Research Initial Review Group (NRRC).
 2014-Present Member of The American Cancer Society, Care and Symptom Management (PCSM) peer review committee.

Faculty Mentoring

2012-Present Mentor and collaborator with Dr. John Wong, Assistant Professor, MGH Institute of Health Professions, School of Nursing, NIH R21 Mechanisms of Post-Stroke Fatigue.
 2012- Present Mentor and faculty collaborator with Dr. Qing Mei Wang, Physiatrist, Spaulding Rehabilitation Hospital. Academic Mini Grant Application, Department of PM&R, Harvard Medical School, and K08 HD074668-02 National Institute of Neurological Disorders and Stroke (NINDS)
 2014 Luo Li PhD, Visiting Research Fellow, School of Physical Education and Sports Science, Soochow University, Suzhou, China. The role of Mcl-1 in stabilization of the NLRP3 inflammasome and the role of IGF-1 mediated demyelination in chemotherapy induced cognitive deficits in mice.
 2009-2013 Faculty collaborator, Dr. Beth Darnall PhD, Assistant Professor, Department of Anesthesiology, OHSU School of Medicine. Medical Research Foundation of Oregon funded proposal "*Pain catastrophizing as a cause of systemic inflammation in women*"
 2008-2011 Faculty Mentor, Dr. Jennifer Loftis PhD, Associate Professor, Dept. of Psychiatry, Oregon Health & Science University School of Medicine. Veterans Association Career Development Award (CDA-2). *Inflammatory mediators in depression and HCV treatment variability*.
 2008 Faculty Mentor for Research Practicum, Dr. Abner Ward MD, Resident, Oregon Health & Science University, SOM Department of Orthopedic Surgery. *The Role of IL-6 in the Fatigue Related to Muscle-Damaging Exercise*.
 2007-2010 Faculty Co-Mentor, Dr. Tasha McDonald MD, Resident, Oregon Health & Science University, School of Medicine, Department of Radiation Medicine application to Medical Research Foundation of Oregon- Early Clinical Investigator and

Radiological Society of North America award. *The Role of IL-1 β , TNF- α , IL-6 in Prostate Cancer Treatment Related Fatigue.*

Postdoctoral Fellow Mentoring

- 2011-2012 Mentor, Dr. Jessica Thaxton, PhD, Post-doctoral Fellow application to Department of Defense Breast Cancer Research Program, Medical Research Foundation of Oregon- Early Clinical Investigator grant.
- 2008-2011 Mentor, Rebecca Ross NP, PhD. Oregon Health & Science University. NRSA Institutional Research (T32) "Research Training in Individual and Family Symptom Management"
- 2009 Faculty Mentor, Dr. Britta Torgrimson PhD, Post-doctoral Fellow, Oregon Health & Science University, School of Nursing, application to Department of Defense Breast Cancer Research Program.

PhD Student Mentoring

- 2009- 2012 Faculty Co-Mentor, Kristianna Weymann RN, BSN, MS, 2009, John. A. Hartford Foundation Building Academic Geriatric Nursing Capacity Predoctoral Scholarship. *Characterization of Fatigue Following Stroke.* Oregon Health & Science University.
- 2008- 2013 PhD Committee Chair, Kris Weymann RN, BSN, MS. *Characterization of fatigue following stroke.* Oregon Health & Science University.
- 2005- 2012 PhD Committee Member: Dallen NP Ormond, Dissertation Title: *Leptin Induced Left Ventricular Hypertrophy in Obese Children and Adolescents*, Oregon health & Science University.
- 2004-2005 PhD Committee Member: Amy Ross RN, MS, CNS, Dissertation Title: *Evidence of the Acute Phase Response in Transient Ischemic Attack Patients*, Oregon Health & Science University.

Mentored Funded Research Grants

(Weymann PI)

2/1/12-11/30/13

Ruth L. Kirschstein National Research Service Awards (NRSA).

Association of poststroke fatigue trajectories with cytokine polymorphisms. By shedding light on whether inflammation plays a role in poststroke fatigue, this research supports the development of therapies targeted to reduce symptom burden in stroke survivors. In addition this research will support improved education to stroke survivors and their families about persistent symptoms such as fatigue, which might decrease symptom distress.

Role: Co-Sponsor with Lillian M. Nail PhD RN

(Thaxton, PI)

1/1/11- 12/31/11

Medical Research Foundation of Oregon- Early Clinical Investigator (ECI).

CMV Infection as a risk factor for persistent CTRF in breast cancer survivors.

Role: Mentor

(Thaxton, PI)

7/1/11-6/30/13

BC103909, The Department of Defense Breast Cancer Research Program Postdoctoral Fellowship Award

Chemotherapy Necessitates Increased Immune Control of Chronic HHVs: A Cause of Persistent Inflammation Enabling Protracted Fatigue in Breast Cancer Survivors.

Role: Mentor

(Darnall PI)

03/01/10-02/28/12

Medical Research Foundation of Oregon

Pain catastrophizing as a cause of systemic inflammation in women.

Role: Collaborator

(McDonald PI)

7/1/07-6/30/08

Medical Research Foundation of Oregon- Early Clinical Investigator (ECI).

The role of IL-1 β , TNF- α and IL-6 in prostate cancer treatment related fatigue.

Role: Mentor

(McDonald PI)

7/1/07-6/30/08

The Radiological Society of North America Research Resident Grant

The role of IL-1 β , TNF- α and IL-6 in prostate cancer treatment related fatigue.

Role: Mentor

Professional Committees

- | | |
|---------------|---|
| 2015-Present | Member, Spaulding Rehabilitation Hospital IRB |
| 2014-Present | MGH Institute of Health Professions, Nominating Committee |
| 2013- Present | Member, Research Operations Committee, MGH Institute of Health Professions |
| 2012- Present | Member of the PhD Executive Committee, MGH Institute of Health Professions |
| 2012- 2012 | OHSU Medical Research Foundation Committee |
| 2011- 2012 | OHSU Conflict of Interest in Research Committee |
| 2010- 2012 | Search committee chair, Biostatistician, Oregon Health & Science University, School of Nursing. |
| 2010 | Search committee member, Director of the Nurse Anesthesia Program, Oregon Health & Science University, School of Nursing. |
| 2011- 2012 | Member, Oregon Health & Science University, SON, Admissions and Progressions Committee |
| 2010- 2012 | Chair, Symptom Management Integrative Learning Community (ILC).
Symptoms such as pain, fatigue, changes in cognition, sleep disruption, and depression have a major negative impact on people of all ages. This ILC seeks to bring together faculty who share a common interest in symptom management, measurement and underlying mechanisms (with a focus on physiological and genomic) with the aim of integrating knowledge development and dissemination of symptom science across all missions. |
| 2007-2012 | OHSU School of Medicine Research Committee |
| 2007-2010 | Chair, Oregon Health & Science University, School of Nursing, PhD Curriculum Committee |
| 2005-2007 | Member, Oregon Health & Science University, School of Nursing, PhD Curriculum Committee |
| 2005-2006 | Member, School of Nursing Research Council |

Community Service Activities

- 2015 Member, MGH Institute of Health Professions, SON Dean Search Committee
- 2011 Task force to develop the Oregon Health & Science University, School of Nursing, *Undergraduate Honors Program in Gerontological Nursing* funded by a Hearst Foundation Education Grant.
- 2011-2012 Co-Director, Oregon Health & Science University Healthy Aging Alliance.
<http://www.ohsu.edu/xd/research/healthy-aging-alliance/>
- 2011- 2012 Associate Director, John A. *Hartford Center* of Geriatric *Nursing* Excellence, Oregon Health & Science University School of Nursing, Portland, OR.
- 2009 Consultant: Pigs for Peace, Great Lakes restoration- “Building the Peace”
- 2009 Member of the development group of the workshop series *Critical Issues in Central Sensitivity: Bench, Translational and Clinical Evidence*